Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

Autor:	Joaquin Herrero, Francisco R García-Arroyo, Antonio Rueda, Cristina Quero, Delvys Rodriguez-Abreu, Ana Blasco, Marta Llanos, María José Casanova, Natividad Martínez-Banaclocha, Jesús Alfaro, David Aguiar, Ruth Alvarez, Luis Merino, Virginia Calvo, Mariano Provencio
Rok vydání:	2018
Předmět:	Oncology Bendamustine Cancer Research medicine.medical_specialty business.industry Follicular lymphoma Hematology medicine.disease Lymphoma Clinical trial 03 medical and health sciences 0302 clinical medicine Refractory immune system diseases hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine Medicine Rituximab Progression-free survival business Prospective cohort study 030215 immunology medicine.drug
Zdroj:	Leukemia & Lymphoma. 60:1576-1579
ISSN:	1029-2403 1042-8194
Popis:	Bendamustine is a drug widely used in the treatment of follicular lymphoma. Although it was initially approved as monotherapy in patients refractory to rituximab [1], better results were obtained w...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2d58ee0ec692c9694f082990415bc9d5 https://doi.org/10.1080/10428194.2018.1542147 Zobrazit plný text záznamu